B-Cell Receptor Signaling in Diffuse Large B-Cell lymphoma

Seminars in Hematology

Volumn 52, Issue 2, 2015, Pages 77-85

  Young, Ryan M ^a   Shaffer, Arthur L ^a   Phelan, James D ^a   Staudt, Louis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; CARRIER PROTEINS AND BINDING PROTEINS; CD79A ANTIGEN; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN CARD 11; TRANSCRIPTION FACTOR 7 LIKE 1; UNCLASSIFIED DRUG; LYMPHOCYTE ANTIGEN RECEPTOR;

CANCER CLASSIFICATION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ASSOCIATION; FEEDBACK SYSTEM; HUMAN; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; LARGE CELL LYMPHOMA; LYMPHOMA; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; B LYMPHOCYTE; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM;

B-LYMPHOCYTES; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; NF-KAPPA B; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 84925258252     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.01.008     Document Type: Review

References (68)

1. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
2. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
3. Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor kappa B activity is required for survival of activated B Cell-like diffuse large B cell lymphoma cells. J Exp Med 2001, 194:1861-1874.
4. Roschewski M., Staudt L.M., Wilson W.H. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 2014, 11:12-23.
5. Ben-Neriah Y., Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011, 12:715-723.
6. Staudt L.M. Oncogenic activation of NF-kappaB. Cold Spring Harbor perspectives in biology 2010, 2:a000109.
7. Lam L.T., Davis R.E., Pierce J., et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005, 11:28-40.
8. Ngo V.N., Davis R.E., Lamy L., et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006, 441:106-110.
9. Thome M., Charton J.E., Pelzer C., Hailfinger S. Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1. Cold Spring Harb Perspect Biol 2010, 2:a003004.
10. Lenz G., Davis R.E., Ngo V.N., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319:1676-1679.
11. Yang Y., Schmitz R., Mitala J., et al. Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms. Cancer Discov 2014, 4:480-493.
12. Dubois S.M., Alexia C., Wu Y., et al. A catalytic-independent role for the LUBAC in NF-kappaB activation upon antigen receptor engagement and in lymphoma cells. Blood 2014, 123:2199-2203.
13. Shaffer A.L., Young R.M., Staudt L.M. Pathogenesis of human B cell lymphomas. Annu Rev Immunol 2012, 30:565-610.
14. Lam L.T., Davis R.E., Ngo V.N., et al. Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci U S A 2008, 105:20798-20803.
15. Yang Y., Shaffer A.L., Emre N.C., et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012, 21:723-737.
16. Lenz G., Wright G.W., Emre N.C., et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008, 105:13520-13525.
17. Ochiai K., Katoh Y., Ikura T., et al. Plasmacytic transcription factor Blimp-1 is repressed by Bach2 in B cells. J Biol Chem 2006, 281:38226-38234.
18. Care M.A., Cocco M., Laye J.P., et al. SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity. Nucl Acids Res 2014, 42:7591-7610.
19. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005, 5:251-262.
20. Lenz G., Nagel I., Siebert R., et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. J Exp Med 2007, 204:633-643.
21. Ruminy P., Etancelin P., Couronne L., et al. The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma. Leukemia 2011, 25:681-688.
22. Liu W., Meckel T., Tolar P., Sohn H.W., Pierce S.K. Intrinsic properties of immunoglobulin IgG1 isotype-switched B cell receptors promote microclustering and the initiation of signaling. Immunity 2010, 32:778-789.
23. Dogan I., Bertocci B., Vilmont V., et al. Multiple layers of B cell memory with different effector functions. Nat Immunol 2009, 10:1292-1299.
24. Martin S.W., Goodnow C.C. Burst-enhancing role of the IgG membrane tail as a molecular determinant of memory. Nat Immunol 2002, 3:182-188.
25. Horikawa K., Martin S.W., Pogue S.L., et al. Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors. J Exp Med 2007, 204:759-769.
26. Dal Porto J.M., Gauld S.B., Merrell K.T., Mills D., Pugh-Bernard A.E., Cambier J. B cell antigen receptor signaling 101. Mol Immunol 2004, 41:599-613.
27. Reth M. Antigen receptor tail clue. Nature 1989, 338:383-384.
28. Rowley R.B., Burkhardt A.L., Chao H.G., Matsueda G.R., Bolen J.B. Syk protein-tyrosine kinase is regulated by tyrosine-phosphorylated Ig alpha/Ig beta immunoreceptor tyrosine activation motif binding and autophosphorylation. J Biol Chem 1995, 270:11590-11594.
29. Rawlings D.J., Scharenberg A.M., Park H., et al. Activation of BTK by a phosphorylation mechanism initiated by SRC family kinases. Science 1996, 271:822-825.
30. Davis R.E., Ngo V.N., Lenz G., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
31. Brunner C., Muller B., Wirth T. Bruton's tyrosine kinase is involved in innate and adaptive immunity. Histol Histopathol 2005, 20:945-955.
32. Lam K.P., Kuhn R., Rajewsky K. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997, 90:1073-1083.
33. Kraus M., Alimzhanov M.B., Rajewsky N., Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004, 117:787-800.
34. Monroe J.G. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2006, 6:283-294.
35. Srinivasan L., Sasaki Y., Calado D.P., et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009, 139:573-586.
36. Chen L., Monti S., Juszczynski P., et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 2013, 23:826-838.
37. Kloo B., Nagel D., Pfeifer M., et al. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 2011, 108:272-277.
38. Tolar P., Hanna J., Krueger P.D., Pierce S.K. The constant region of the membrane immunoglobulin mediates B cell-receptor clustering and signaling in response to membrane antigens. Immunity 2009, 30:44-55.
39. Gazumyan A., Reichlin A., Nussenzweig M.C. Ig beta tyrosine residues contribute to the control of B cell receptor signaling by regulating receptor internalization. J Exp Med 2006, 203:1785-1794.
40. Busman-Sahay K., Drake L., Sitaram A., Marks M., Drake J.R. Cis and trans regulatory mechanisms control AP2-mediated B cell receptor endocytosis via select tyrosine-based motifs. PLoS One 2013, 8:e54938.
41. Xu Y., Harder K.W., Huntington N.D., Hibbs M.L., Tarlinton D.M. Lyn tyrosine kinase: accentuating the positive and the negative. Immunity 2005, 22:9-18.
42. Compagno M., Lim W.K., Grunn A., et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459:717-721.
43. Srinivasula S.M., Ashwell J.D. A20: more than one way to skin a cat. Mol Cell 2011, 44:511-512.
44. Agathangelidis A., Darzentas N., Hadzidimitriou A., et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood 2012, 119:4467-4475.
45. Catera R., Silverman G.J., Hatzi K., Seiler T., Didier S., Zhang L., et al. Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. Mol Med 2008, 14:665-674.
46. Chu C.C., Catera R., Zhang L., et al. Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. Blood 2010, 115:3907-3915.
47. Duhren-von Minden M., Ubelhart R., Schneider D., et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012, 489:309-312.
48. Sebastian E., Alcoceba M., Balanzategui A., et al. Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype. Am J Pathol 2012, 181:1879-1888.
49. Benschop R.J., Brandl E., Chan A.C., Cambier J.C. Unique signaling properties of B cell antigen receptor in mature and immature B cells: implications for tolerance and activation. J Immunol 2001, 167:4172-4179.
50. Gross A.J., Lyandres J.R., Panigrahi A.K., Prak E.T., DeFranco A.L. Developmental acquisition of the Lyn-CD22-SHP-1 inhibitory pathway promotes B cell tolerance. J Immunol 2009, 182:5382-5392.
51. Ngo V.N., Young R.M., Schmitz R., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119.
52. Jiang Z., Georgel P., Li C., et al. Details of Toll-like receptor:adapter interaction revealed by germ-line mutagenesis. Proc Natl Acad Sci U S A 2006, 103:10961-10966.
53. Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416:603-607.
54. Chaturvedi A., Dorward D., Pierce S.K. The B cell receptor governs the subcellular location of Toll-like receptor 9 leading to hyperresponses to DNA-containing antigens. Immunity 2008, 28:799-809.
55. O'Neill S.K., Veselits M.L., Zhang M., et al. Endocytic sequestration of the B cell antigen receptor and toll-like receptor 9 in anergic cells. Proc Natl Acad Sci U S A 2009, 106:6262-6267.
56. Wang J.Q., Jeelall Y.S., Beutler B., Horikawa K., Goodnow C.C. Consequences of the recurrent MYD88(L265P) somatic mutation for B cell tolerance. J Exp Med 2014, 211:413-426.
57. Schmitz R., Ceribelli M., Pittaluga S., Wright G., Staudt L.M. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Biol 2014, 4.
58. Schmitz R., Young R.M., Ceribelli M., et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012, 490:116-120.
59. Sander S., Calado D.P., Srinivasan L., et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012, 22:167-179.
60. Murre C., McCaw P.S., Baltimore D. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell 1989, 56:777-783.
61. Pfeifer M., Grau M., Lenze D., et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013, 110:12420-12425.
62. Young R.M., Staudt L.M. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013, 12:229-243.
63. Wilson W.H., Gerecitano J.F., Goy A., et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. ASH Abstract 2012.
64. Furman R.R., Cheng S., Lu P., et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med 2014, 370:2352-2354.
65. Woyach J.A., Furman R.R., Liu T.M., et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014, 370:2286-2294.
66. Cheng S., Guo A., Lu P., Ma J., Coleman M., Wang Y.L. Functional Characterization of BTK mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia 2014, Epub ahead of print. 10 October 2014; doi: 10.1038/leu.2014.263.
67. Mathews Griner L.A., Guha R., Shinn P., et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 2014, 111:2349-2354.
68. Ceribelli M., Kelly P.N., Shaffer A.L., et al. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A 2014, 111:11365-11370.